Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 18, Issue 3, Pages 314-321Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458511421054
Keywords
BG-12; demographics; disease modifying therapies; multiple sclerosis; relapsing/remitting; subpopulation
Categories
Funding
- Biogen Idec, Inc.
- Swiss MS Society
- Czech Ministry of Education [MSM 0021620849]
- UCLH/UCL Comprehensive Biomedical Research Centre (CBRC)
- University Hospital Basel
- Swiss National Research Foundation
- European Union
- Gianni Rubatto Foundation
- Novartis Foundation
- Roche Research Foundation
- BayerSchering
- Biogen Idec
- Merck-Serono
- Novartis
- Teva
- GlaxoSmithKline
- Antisense Therapeutics
- Bayer
- MSD
- Pfizer
- Sanofi-Aventis
- Actelion
- Roche
- UCB
- Schering AG
- NIHR UCLH Comprehensive Biomedical Research Centre
- MS Society of Great Britain and Northern Ireland
- MRC
- Wellcome Trust
Ask authors/readers for more resources
Background: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo. Objective: In this analysis, the effect of BG-12 240 mg three times daily on the number of Gd+ lesions from weeks 12 to 24 was evaluated in subgroups based on baseline disease characteristics and demographics. Methods: Two hundred and fifty-seven patients were randomized equally to receive BG-12 (120 mg once daily or three times daily or 240 mg three times daily) or placebo. Results: BG-12 240 mg three times daily significantly reduced the number of new Gd+ lesions compared with placebo in the following subgroups: Expanded Disability Status Scale (EDSS) score <= 2.5 (74%), EDSS score > 2.5 (63%), no Gd+ lesions (80%), >= 1 Gd+ lesion (55%), age < 40 years (49%), age >= 40 years (89%), female patients (81%), disease duration <= 6 years (81%) and disease duration > 6 years (54%) (all comparisons p < 0.05). Conclusion: BG-12 demonstrated efficacy in patients with RRMS by decreasing new Gd+ lesion development across a range of subgroups defined by baseline disease characteristics or demographics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available